Saturday 17 October 2026
Export HROW’s income statement to Excel — free account
Harrow, Inc.
HROW Healthcare Drug Manufacturers Specialty & Generic
Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
27.28
1.47
−5.11%
Follow HROW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(9.57%) | (8.47%) | (35.43%) | (116.07%) | |
Piotroski F-Score |
6 | 6 | 5 | 4 | |
| (1.40%) | (1.30%) | (3.82%) | (9.77%) | ||
ROIC |
8.08% | 8.58% | 5.44% | (0.77%) | |
Return on Tangible Assets |
(4.32%) | (4.33%) | (10.84%) | (28.61%) | |
Average Days of Receivables |
113.28 | 148.65 | 137.56 | 157.02 | |
Free Cash Flow per Share |
(0.55) | 1.16 | (0.10) | (0.35) | |
Free Cash Flow |
(20.62) | 42.76 | (3.89) | (13.08) | |
Capital Expenditures |
(38.29) | (1.10) | (19.09) | (19.33) | |
| Other line items | |||||
Cash ROIC |
(5.67%) | 11.61% | (0.94%) | (3.34%) | |
Accounts Receivable Turnover |
3.81 | 2.40 | 3.01 | 2.79 | |
Accounts Payable Turnover |
2.80 | 1.63 | 2.01 | 2.48 | |
Inventory Turnover |
5.53 | 5.61 | 5.11 | 5.17 | |
Average Days of Payables |
115.71 | 225.44 | 157.49 | 168.84 | |
Days of Inventory on Hand |
73.65 | 72.66 | 86.55 | 83.82 | |
Tax Rate |
0.00 | 0.00 | 0.02 | 0.00 | |
Research and Development Expense of Revenue |
5.59% | 7.69% | 8.86% | 10.53% | |
Selling, General and Administrative Expense of Revenue |
57.75% | 56.16% | 57.93% | 63.75% | |
Share Based Compensation of Revenue |
5.40% | 4.59% | 4.39% | 5.33% | |
Interest Coverage |
1.10 | 1.26 | 0.85 | (0.12) | |
Operating CF/Net income |
(3.54) | (8.54) | (1.02) | (0.17) | |
Depreciation/Fixed assets |
7.23 | 7.28 | 7.59 | 8.16 | |
Capex/Depreciation |
(1.57) | (0.05) | (0.80) | (0.80) | |
Revenue per Share |
6.73 | 7.41 | 7.22 | 7.38 | |
Operating CF per Share |
0.48 | 1.19 | 0.41 | 0.17 | |
Capex per Share |
(1.03) | (0.03) | (0.51) | (0.52) | |
Capex to Sales |
0.15 | 0.00 | 0.07 | 0.07 |
Columns are period end dates